Latest News: Rare Element Resources Ltd., Joe’s Jeans (NASDAQ:JOEZ), Anthera Pharmaceuticals (NASDAQ:ANTH), Wells Fargo & Company (NYSE:WFC)

Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), announced that a detailed overview of its AR-V7 clinical trial assay will be presented tonight at a poster session during the 22nd Annual Prostate Cancer Foundation Scientific Retreat in Washington, DC.
Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) shares decreased -1.50% in last trading session and ended the day at $11.15. TKAI has a return on assets of -35.00%. Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) quarterly performance is -18.55%.

Rare Element Resources Ltd. (NYSEMKT:REE) ended the last trading day at $0.30. Company weekly volatility is calculated as 6.94%. Rare Element Resources Ltd. (NYSEMKT:REE) showed a weekly performance of 0.33%.

Rare Element Resources Ltd. (NYSE MKT: REE), a publicly traded, strategic materials company focused on delivering rare earth products for technology and defense applications by advancing the Bear Lodge Critical Rare Earth Project located in northeast Wyoming, announced that it has completed the 2015 condemnation drill program at the planned physical upgrade plant (PUG) site for the Bear Lodge Project. The program consisted of six reverse circulation drill holes for a total of 3,000 feet and geotechnical work that included six shallow holes and three test pits in the area of the PUG.

On 08 October, Joe’s Jeans Inc. (NASDAQ:JOEZ) shares decreased -4.25% and was closed at $0.34. JOEZ EPS growth in last 5 year was -24.80%. Joe’s Jeans Inc. (NASDAQ:JOEZ) year to date (YTD) performance is 3.00%.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) shares decreased -3.92% in last trading session and ended the day at $6.00. ANTH has a return on assets of -122.70%. Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) quarterly performance is -27.93%.

On 2 October, Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) announced the initiation of the SOLUTION (Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in People With Cystic Fibrosis) Phase 3 clinical study evaluating the efficacy and safety of Sollpura(R) (liprotamase), a microbial derived, biotech pancreatic enzyme replacement therapy (PERT), compared to an approved, porcine-derived, enteric-coated product for the treatment of exocrine pancreatic insufficiency (EPI).

Wells Fargo & Company (NYSE:WFC) caters to the Financial space. It has a net profit margin of 44.70% and weekly performance is 2.14%. On the last day of trading company shares ended up at $52.54. Wells Fargo & Company (NYSE:WFC) distance from 50-day simple moving average (SMA50) is -2.35%.

Wells Fargo & Company (NYSE:WFC) announced $6 million in neighborhood revitalization donations with 69 grants to nonprofits. “Wells Fargo is pleased to support these nonprofits that are leading efforts to revitalize and position neighborhoods for long-term success,” said Martin Sundquist, executive director of the Wells Fargo Housing Foundation. “The Priority Markets Program is one of thousands of ways we work together with nonprofits to support local communities.